ArticleJournal of translational medicine2026
Methionine addiction in oral squamous cell carcinoma: a metabolic vulnerability targeted by engineered bacteria.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metabolic reprogramming is a defining hallmark of malignant transformation, and tumor-specific amino acid addiction has emerged as a promising therapeutic axis for precision oncology. Oral squamous cell carcinoma (OSCC) is an aggressive head and neck malignancy marked by limited curative options, frequent recurrence, and poor long-term survival. Cumulative multi-omics and clinical evidence consistently confirm widespread methionine addiction across OSCC lesions, yet conventional systemic methionine restriction strategies are hampered by severe off-target organ toxicity and insufficient tumor selectivity. Engineered attenuated Salmonella typhimurium strain SGN1 represents a tumor microenvironment-homing live biotherapeutic platform that achieves localized intratumoral methionine degradation with minimal systemic perturbation. Preclinical data across immunocompetent murine models and patient-derived organoids demonstrate robust anti-OSCC activity alongside controllable antibiotic-mediated clearance and broad systemic biosafety. This Commentary contextualizes SGN1 within the broader landscape of microbe-mediated amino acid depletion therapies, systematically dissects the core metabolic mechanisms underpinning OSCC methionine addiction, elaborates preclinical efficacy and safety profiles of SGN1, expands critical discussion of translational bottlenecks, and outlines structured clinical development frameworks for live bacterial metabolic therapeutics. By integrating comparative analysis of arginine and tryptophan-targeted microbial interventions, this work provides balanced, forward-looking insights to advance stratified, minimally invasive precision treatment for methionine-addicted OSCC and other solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.